These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 7375639)

  • 1. Estimation of whole-body doses by means of chromosome aberrations observed in survivors of the Hiroshima A-bomb.
    Randolph ML; Brewen JG
    Radiat Res; 1980 May; 82(2):393-407. PubMed ID: 7375639
    [No Abstract]   [Full Text] [Related]  

  • 2. The F value for chromosome aberrations in atomic bomb survivors does not provide evidence for a primary contribution of neutrons to the dose in Hiroshima.
    Kodama Y; Ohtaki K; Awa AA; Nakano M; Itoh M; Nakamura N
    Radiat Res; 1999 Nov; 152(5):558-62. PubMed ID: 10521934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct biological evidence for a significant neutron dose to survivors of the Hiroshima atomic bomb.
    Brenner DJ
    Radiat Res; 1996 Apr; 145(4):501-7. PubMed ID: 8600511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological effectiveness of neutrons from Hiroshima bomb replica: results of a collaborative cytogenetic study.
    Dobson RL; Straume T; Carrano AV; Minkler JL; Deaven LL; Littlefield LG; Awa AA
    Radiat Res; 1991 Nov; 128(2):143-9. PubMed ID: 1947011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of gamma and neutron radiation to posterior lenticular opacities among atomic bomb survivors in Hiroshima and Nagasaki.
    Otake M; Schull WJ
    Radiat Res; 1982 Dec; 92(3):574-95. PubMed ID: 7178422
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose-response relationship of neutrons and gamma rays to leukemia incidence among atomic bomb survivors in Hiroshima and Nagasaki by type of leukemia, 1950--1971.
    Ishimaru T; Otake M; Ischimaru M
    Radiat Res; 1979 Feb; 77(2):377-94. PubMed ID: 286375
    [No Abstract]   [Full Text] [Related]  

  • 7. Stable chromosome aberrations among A-bomb survivors: an update.
    Stram DO; Sposto R; Preston D; Abrahamson S; Honda T; Awa AA
    Radiat Res; 1993 Oct; 136(1):29-36. PubMed ID: 8210335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of various aspects of atomic bomb dose estimation at RERF using data on acute radiation symptoms.
    Gilbert ES; Ohara JL
    Radiat Res; 1984 Oct; 100(1):124-38. PubMed ID: 6494426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Review of 30 years study of Hiroshima and Nagasaki atomic bomb survivors. The Japan Radiation Research Society Chiba. Japan, September, 1975].
    Gus'kova AK; Sadchikova EN
    Med Radiol (Mosk); 1977 Aug; 22(8):69-77. PubMed ID: 927066
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose-response relationship of neutron and gamma rays to chromosomally aberrant cells among atomic bomb survivors in Hiroshima and Nagasaki.
    Otake M
    J Radiat Res; 1979 Dec; 20(4):307-21. PubMed ID: 536952
    [No Abstract]   [Full Text] [Related]  

  • 11. Comments on "Direct biological evidence for a significant neutron dose to survivors of the Hiroshima atomic bomb" by D.J. Brenner (Radiat. Res. 145, 501-507, 1996).
    Schmid E; Bauchinger M
    Radiat Res; 1996 Oct; 146(4):479-82. PubMed ID: 8927721
    [No Abstract]   [Full Text] [Related]  

  • 12. Effective dose of A-bomb radiation in Hiroshima and Nagasaki as assessed by chromosomal effectiveness of spectrum energy photons and neutrons.
    Sasaki MS; Endo S; Ejima Y; Saito I; Okamura K; Oka Y; Hoshi M
    Radiat Environ Biophys; 2006 Jul; 45(2):79-91. PubMed ID: 16807767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choice of model and uncertainties of the gamma-ray and neutron dosimetry in relation to the chromosome aberrations data in Hiroshima and Nagasaki.
    Rühm W; Walsh L; Chomentowski M
    Radiat Environ Biophys; 2003 Jul; 42(2):119-28. PubMed ID: 12844221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental derivation of relative biological effectiveness of A-bomb neutrons in Hiroshima and Nagasaki and implications for risk assessment.
    Sasaki MS; Nomura T; Ejima Y; Utsumi H; Endo S; Saito I; Itoh T; Hoshi M
    Radiat Res; 2008 Jul; 170(1):101-17. PubMed ID: 18582156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetic validation of DS02R1-estimated dose for atomic bomb survivors in Hiroshima and Nagasaki with FISH.
    Kodama Y; Nakamura N; Nakano M; Ohtaki K; Hamasaki K; Noda A
    Int J Radiat Biol; 2024; 100(8):1155-1164. PubMed ID: 38991111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose estimation for atomic bomb survivor studies: its evolution and present status.
    Cullings HM; Fujita S; Funamoto S; Grant EJ; Kerr GD; Preston DL
    Radiat Res; 2006 Jul; 166(1 Pt 2):219-54. PubMed ID: 16808610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of relative biological effectiveness dependence on linear energy transfer for low-LET radiations.
    Hunter N; Muirhead CR
    J Radiol Prot; 2009 Mar; 29(1):5-21. PubMed ID: 19225189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermoluminescence dosimetry of gamma rays from the atomic bomb at Hiroshima using the predose technique.
    Nagatomo T; Ichikawa Y; Ishii H; Hoshi M
    Radiat Res; 1988 Feb; 113(2):227-34. PubMed ID: 3340729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The present state of atomic bomb survivors, with special reference to biological late-effects of radiation].
    Kamada N
    Rinsho Byori; 2004 Mar; 52(3):217-22. PubMed ID: 15137319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications of the neutron effect contribution in the solid cancer data of the A-bomb survivors.
    Kellerer AM; Rühm W; Walsh L
    Health Phys; 2006 Jun; 90(6):554-64. PubMed ID: 16691103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.